- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06175221
Autologous TLPO Vaccine Basket
A Prospective, Open-Label, All-Comers Phase IIa Trial of The Tumor Lysate, Particle Only (TLPO) Cancer Vaccine in Solid Tumor Malignancies
The goal of this clinical trial is to learn about TLPO cancer vaccine in cases of solid tumor malignancies. The main objectives it aims to learn about are:
- What is the time to progression/recurrence of disease after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies?
- What is the overall survival after vaccination with the autologous TLPO vaccine in multiple solid tumor malignancies?
- What are the safety characteristics of autologous TLPO using standardized criteria (Common Terminology Criteria for Adverse Events v5.0)
- Does TPLO generate an immune response?
- Determine the presence, rate, and duration of any disease control response affected by TPLO.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with any stage solid tumor malignancy will be identified and screened for study inclusion and exclusion criteria. Eligible patients will be counseled and consented for tissue procurement. Enrolled patients will undergo either surgical resection or core needle biopsy of their tumor, with a minimum of 1mg of tumor sterilely frozen. This tumor sample will be shipped via FedEx to our central facility in Greenville, SC, for vaccine preparation.
As indicated by standard treatments determined by the treating team, if a patient will require systemic therapy such as cytotoxic chemotherapy and/or radiation therapy, vaccination with the TLPO vaccine will not begin until after such treatments have been completed. However, patients on maintenance non-immunosuppressive therapy to include targeted therapy, immunotherapy including checkpoint inhibitors, and/or hormonal therapy may start the vaccine trial after demonstrating tolerance of these therapies for three months prior to first inoculation.23 Vaccines will be produced by loading TL into pre-prepared YCWP, as a single dose vial of 1.0 x 108 TLPO, and then labeled with the patient's unique study number. The TLPO vaccine will then be sent back to the site. The site will receive six single dose vials to be injected intradermally at 0, 1, and 2 months followed by boosters at 6, 9, and 12 months in the same lymph node draining area, preferably the anterior thigh. Safety data will be collected for any local or systemic toxicity. Safety data will be graded and reported per CTCAE v5.0. Time to progression and additional study endpoints will be monitored as guided for current standard treatments by NCCN. Participants will be followed by their treatment team at a minimum of once every six months for the two-year study period. If the treatment team suspects recurrence by either symptoms, imaging, or other means, biopsy and pathologic confirmation will be obtained. Time to recurrence will be based on time from initial inoculation of vaccine to time of confirmed recurrence. Overall survival will be based on time from initial inoculation of the vaccine to time of death. Patients will be treated by current standard therapies for their recurrence. Safety and tumor response will be assessed per RECIST and iRECIST on their standard follow-up scans.
Blood (50cc) will be collected from patients prior to each inoculation for immunologic testing of the patient's T-cell response and/or future scientific purposes.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Pauline Nichols, PA
- Phone Number: 864-312-5156
- Email: pauline.nichol@eliosholdings.com
Study Locations
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
- Recruiting
- Southside Medical Center
-
Contact:
- Thaer Joudeh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient must be ≥18 years of age.
- Stage I-IV patients.
- Demonstrated tolerance of maintenance or adjuvant immunotherapy, targeted therapy, and/or hormonal therapy for three doses (if maintenance therapy is indicated)
- ECOG 0-1 performance.
- Patient must have a predicted life expectancy of ≥ 6 months.
- No uncontrolled or life-threatening health conditions.
- No active, acute infections
Patient must have the following laboratory values (obtained ≤28 days prior to enrollment):
- Serum creatinine <2 × upper limit of normal (ULN) or if higher than normal range, calculated creatinine clearance (CrCL) must be ≥30 mL/min/1.73 m2; actual body weight must be used for CrCL unless BMI >30 kg/m2 then lean body weight must be used.
- Total bilirubin ≤1.5 × ULN unless has known history of Gilbert's syndrome (in which case, total bilirubin must be ≤3 × ULN).
- AST and ALT ≤2.5 × ULN, or ≤5 × ULN if due to liver involvement by tumor.
- Hemoglobin ≥9.0 g/dL.
- Platelets ≥100 × 109 cells/L.
- Absolute neutrophil count ≥1.5 ×109 cells/L (without the use of hematopoietic growth factors).
- Corrected QT interval (QTc) <470 ms for females and <450 ms for males (as calculated by the Fridericia correction formula).
- Completion of standard adjuvant therapy to include chemotherapy, radiation therapy, and/or other immunosuppressive therapy as clinically indicated.
- Women of childbearing potential (WOCBP) and males with female partners of child- bearing potential must agree to use adequate birth control throughout their participation and for 90 days following the last inoculation.
- Patient must have a site of disease with planned incisional or excisional procedure expected to result in sufficient tissue for vaccine creation, or must be amenable to biopsy and be a candidate for tumor biopsy with anticipated sufficient tumor tissue resulting to vaccine creation.
Exclusion Criteria:
- Steroids, immunosuppressive therapy (to include mTOR inhibitors), or cytotoxic chemotherapy within 30 days of enrollment.
- Involved in other clinical trials.
- ECOG ≥2
- Pregnancy and/or breast feeding.
- Untreated or progressing brain metastases. Treated stable brain metastases that have not progressed for at least 3 months will be permitted at the PI's discretion.
- Rapidly progressive disease or visceral crisis
- Patient has undergone or is anticipated to undergo organ transplantation including allogeneic or autologous stem-cell transplantation, at any time
- Patient has a diagnosis of immunodeficiency, either primary or acquired.
- Patient has current second malignancy at other sites (exceptions: nonmelanomatous skin cancer, adequately treated in situ carcinoma [e.g., cervical], or indolent prostate cancer under observation). A history of other malignancies is allowed as long as patient has been free of recurrence for ≥2 years, or if the patient has been treated with curative intent within the past 2 years and, in the opinion of the Investigator, is unlikely to have a recurrence.
- Patient has active and clinically significant bacterial, fungal, or viral infection, including known Hepatitis A, B, or C or HIV (testing not required).
- Patient has received live vaccines within the past 30 days (inactivated vaccines are allowed; seasonal vaccines should be up to date >30 days prior to administration of TLPO).
- History of any of the following ≤6 months before first dose: congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, ongoing symptomatic cardiac arrhythmias of >Grade 2, pulmonary embolism, or symptomatic cerebrovascular events, or any other serious cardiac condition (e.g., pericardial effusion or restrictive cardiomyopathy). Chronic atrial fibrillation on stable anticoagulant therapy is allowed.
- Patient has any medical or social condition that, in the opinion of the Investigator, might place a patient at increased risk, affect compliance, or confound safety or other clinical study data interpretation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment - Investigational Product
Product Name: Tumor lysate, particle only (TLPO) vaccine Dosage Form: Intradermal Injection Unit Dose: 1x10^8 autologous tumor lysate-loaded, yeast cell wall particles Route of Administration: Intradermal; primary vaccine series at 0, 1, 2 months followed by boosters at 6, 9, and 12 months Physical Description: 250 uL clear liquid vials Manufacturer: Elios Therapeutics, LLC |
A novel technology in which a patient's tumor lysate (TL) is loaded into microparticles for DC phagocytosis and antigen processing allows for vaccine efficacy, while minimizing tissue demands by only requiring approximately 250-500ug of tumor.
Immature DCs avidly phagocytose small particles in the range of 1-5 microns.
Tumor tissue collected from the patient undergoes a process of freeze-thaw cycling to create a TL suspension.
The microparticles, yeast-cell wall particles (YCWP), are created from Saccharomyces cerevisiae by NaOH/HCl digestion of all non-cell wall components and washed, producing β-glycan shells.
The TL is then loaded into these YCWP.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Disease Progression
Time Frame: 24 months
|
To determine time to progression per RECIST criteria after inoculation with the TLPO vaccine.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events per CTCAE v5.0
Time Frame: 24 months
|
Treatment-related adverse events per CTCAE v5.0 will be analyzed to determine to safety and tolerability of the vaccine.
|
24 months
|
Overall survival (OS) after vaccination
Time Frame: Time from inoculation to time of death
|
The time from inoculation to time of death will be recorded and OS rate will be calculated.
|
Time from inoculation to time of death
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune Response after vaccination
Time Frame: 24 months
|
Blood samples collected during the trial will be analyzed for the presence or absence of immunologic response markers.
|
24 months
|
Disease Control Rate
Time Frame: 24 months
|
To determine the disease control rate after vaccination.
|
24 months
|
Objective Response Rate
Time Frame: 24 months
|
To determine the objective response rate after vaccination.
|
24 months
|
Duration of Response
Time Frame: 24 months
|
To determine the duration of response after vaccination.
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET-Bas-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Tumor lysate, particle only (TLPO) vaccine
-
Edward ZigaTerminatedGlioma | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | High Grade GliomaUnited States
-
Macarena De La Fuente, MDCompletedGlioblastoma Multiforme | High Grade Glioma | Malignant Glioma | Anaplastic AstrocytomaUnited States
-
National Cancer Institute (NCI)CompletedSarcoma | Neuroectodermal Tumors, Primitive, Peripheral | Neuroblastoma | Rhabdomyosarcoma-Embryonal | Rhabdomyosarcoma- AlveolarUnited States
-
Jonsson Comprehensive Cancer CenterCompletedAdult Diffuse Astrocytoma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain Tumor | Adult OligoastrocytomaUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
Macarena De La Fuente, MDActive, not recruitingSarcoma | Soft Tissue Sarcoma | Bone SarcomaUnited States
-
University of Michigan Rogel Cancer CenterCompletedSarcoma | Neuroblastoma | Wilm's TumorUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
Dartmouth-Hitchcock Medical CenterUniversity of VermontTerminatedGlioblastoma
-
N.N. Petrov National Medical Research Center of...UnknownSarcoma | Neoplasms, Connective and Soft TissueRussian Federation